167 related articles for article (PubMed ID: 28904865)
1. Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII.
Knedlík T; Vorlová B; Navrátil V; Tykvart J; Sedlák F; Vaculín Š; Franěk M; Šácha P; Konvalinka J
FEBS Open Bio; 2017 Sep; 7(9):1362-1378. PubMed ID: 28904865
[TBL] [Abstract][Full Text] [Related]
2. Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs.
Rovenská M; Hlouchová K; Sácha P; Mlcochová P; Horák V; Zámecník J; Barinka C; Konvalinka J
Prostate; 2008 Feb; 68(2):171-82. PubMed ID: 18076021
[TBL] [Abstract][Full Text] [Related]
3. Expression of glutamate carboxypeptidase II in human brain.
Sácha P; Zámecník J; Barinka C; Hlouchová K; Vícha A; Mlcochová P; Hilgert I; Eckschlager T; Konvalinka J
Neuroscience; 2007 Feb; 144(4):1361-72. PubMed ID: 17150306
[TBL] [Abstract][Full Text] [Related]
4. Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding.
Barinka C; Mlcochová P; Sácha P; Hilgert I; Majer P; Slusher BS; Horejsí V; Konvalinka J
Eur J Biochem; 2004 Jul; 271(13):2782-90. PubMed ID: 15206943
[TBL] [Abstract][Full Text] [Related]
5. Detection and quantitation of glutamate carboxypeptidase II in human blood.
Knedlík T; Navrátil V; Vik V; Pacík D; Šácha P; Konvalinka J
Prostate; 2014 May; 74(7):768-80. PubMed ID: 24647901
[TBL] [Abstract][Full Text] [Related]
6. Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
Vornov JJ; Peters D; Nedelcovych M; Hollinger K; Rais R; Slusher BS
Neurochem Res; 2020 Jun; 45(6):1256-1267. PubMed ID: 31749072
[TBL] [Abstract][Full Text] [Related]
7. A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging.
Vorlová B; Sedlák F; Kašpárek P; Šrámková K; Malý M; Zámečník J; Šácha P; Konvalinka J
Prostate; 2019 Feb; 79(2):126-139. PubMed ID: 30256431
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.
Naushad SM; Shree Divyya P; Janaki Ramaiah M; Alex Stanley B; Prasanna Lakshmi S; Vishnupriya J; Kutala VK
Cancer Genet; 2015 Nov; 208(11):552-8. PubMed ID: 26471812
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
10. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Barinka C; Sácha P; Sklenár J; Man P; Bezouska K; Slusher BS; Konvalinka J
Protein Sci; 2004 Jun; 13(6):1627-35. PubMed ID: 15152093
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).
Tykvart J; Navrátil V; Sedlák F; Corey E; Colombatti M; Fracasso G; Koukolík F; Bařinka C; Sácha P; Konvalinka J
Prostate; 2014 Dec; 74(16):1674-90. PubMed ID: 25262926
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Divyya S; Naushad SM; Addlagatta A; Murthy PV; Reddy ChR; Digumarti RR; Gottumukkala SR; Kumar A; Rammurti S; Kutala VK
Gene; 2012 Apr; 497(2):273-9. PubMed ID: 22310383
[TBL] [Abstract][Full Text] [Related]
13. N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Neale JH; Yamamoto T
Prog Neurobiol; 2020 Jan; 184():101722. PubMed ID: 31730793
[TBL] [Abstract][Full Text] [Related]
14. Association of glutamate carboxypeptidase II (GCPII) haplotypes with breast and prostate cancer risk.
Divyya S; Naushad SM; Addlagatta A; Murthy PV; Reddy ChR; Digumarti RR; Gottumukkala SR; Subbarao SA; Kutala VK
Gene; 2013 Mar; 516(1):76-81. PubMed ID: 23266799
[TBL] [Abstract][Full Text] [Related]
15. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II.
Barinka C; Rinnová M; Sácha P; Rojas C; Majer P; Slusher BS; Konvalinka J
J Neurochem; 2002 Feb; 80(3):477-87. PubMed ID: 11905994
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
[TBL] [Abstract][Full Text] [Related]
17. Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury.
Gao Y; Xu S; Cui Z; Zhang M; Lin Y; Cai L; Wang Z; Luo X; Zheng Y; Wang Y; Luo Q; Jiang J; Neale JH; Zhong C
J Neurochem; 2015 Jul; 134(2):340-53. PubMed ID: 25872793
[TBL] [Abstract][Full Text] [Related]
18. Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.
Navrátil M; Tykvart J; Schimer J; Pachl P; Navrátil V; Rokob TA; Hlouchová K; Rulíšek L; Konvalinka J
FEBS J; 2016 Jul; 283(13):2528-45. PubMed ID: 27208881
[TBL] [Abstract][Full Text] [Related]
19. Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery.
Tykvart J; Schimer J; Bařinková J; Pachl P; Poštová-Slavětínská L; Majer P; Konvalinka J; Šácha P
Bioorg Med Chem; 2014 Aug; 22(15):4099-108. PubMed ID: 24954515
[TBL] [Abstract][Full Text] [Related]
20. Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition.
Sedlák F; Kvasnička A; Marešová B; Brumarová R; Dobešová D; Dostálová K; Šrámková K; Pehr M; Šácha P; Friedecký D; Konvalinka J
ACS Chem Neurosci; 2024 Apr; 15(7):1342-1355. PubMed ID: 38377674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
